Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) [EBShield Study]

NCT06073132 is registered in ClinicalTrials.gov with TWi Biotechnology, Inc. as lead sponsor.

NCT NCT06073132
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06073132 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) [EBShield Study]
Lead sponsor
TWi Biotechnology, Inc.
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
April 4, 2024
Completion date
March 31, 2027
Enrollment
80 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

generalized epidermolysis bullosa simplex